Woodline Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Woodline Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.49M	Sell	100,478 -50,169	-33%	-$1.2M	0.01%	780
2025 Q4	$3.52M	Buy	150,647 +169	+0.1%	+$3.77K	0.01%	691
2025 Q3	$2.96M	Hold	150,478	–	–	0.01%	670
2025 Q2	$3.27M	Sell	150,478 -56,000	-27%	-$1.32M	0.02%	636
2025 Q1	$5.01M	Sell	206,478 -46,491	-18%	-$1.05M	0.03%	510
2024 Q4	$5.28M	Sell	252,969 -53,489	-17%	-$1.15M	0.04%	476
2024 Q3	$6.09M	Sell	306,458 -197,277	-39%	-$3.66M	0.05%	366
2024 Q2	$7.8M	Sell	503,735 -23	-0%	-$358	0.07%	282
2024 Q1	$8.03M	Buy	+503,758	New	+$7.59M	0.07%	300
2023 Q3	–	Sell	-253,325	Closed	-$3.4M	–	618
2023 Q2	$3.4M	Buy	+253,325	New	+$3.65M	0.04%	355

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Woodline Partners's CPRX Position: Q1 2026 in Review

Woodline Partners reduced its Catalyst Pharmaceutical (CPRX) stake by 33% in Q1 2026, selling an estimated $1.2M and leaving 100,478 shares worth $2.49M. The position accounts for 0.01% of the portfolio, ranked #780.

Woodline Partners first reported a position in CPRX in Q2 2023 and has held it in 10 quarters since. The position peaked at $8.03M in Q1 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Woodline Partners held 100,478 shares of Catalyst Pharmaceutical worth $2.49M as of Q1 2026.
Woodline Partners sold 50,169 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.2M.
Catalyst Pharmaceutical made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #780 holding.
Woodline Partners first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 10 quarters since.
Woodline Partners's Catalyst Pharmaceutical position peaked at $8.03M in Q1 2024.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.